ALNY Alnylam Pharmaceuticals, Inc.

147.82USD-1.06%Mkt Cap: 19.80B USDP/E: 7.47

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for h…

Insiders, last 90 days2 buys
Institutional holders20 on file

Key Statistics

Company
Market Cap19.80B USD
Enterprise Value19.42B USD
Revenue (TTM)5.01B USD
Gross Profit3.03B USD
Net Income (TTM)313.75M USD
Revenue/Share37.65 USD
Last Price147.82 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees2.5K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)7.47
P/E (Forward)14.92
PEG0.20
EV/EBITDA18.80
EV/Revenue3.87
P/S3.95
P/B5.49
EPS (TTM)19.40 USD
EPS (Forward)9.90 USD
52W Range
146.510% of range479.79
52W High479.79 USD
52W Low146.51 USD
Profitability
Gross Margin81.64%
Oper. Margin19.50%
EBITDA Margin20.61%
Profit Margin8.45%
ROE39.76%
ROA6.32%
ROIC—
ROCE14.33%
Growth
Revenue Growth16.70%
Earnings Growth633.50%
Cash Flow & Leverage
Operating CF524.08M USD
CapEx (TTM)58.70M USD
FCF Margin6.53%
FCF Yield1.65%
Net Debt-590.40M USD
Net Debt/EBITDA-0.57
Net Debt/FCF-1.80
Balance Sheet
Debt/Equity1.62
Current Ratio2.48
Quick Ratio2.27
Book Value/Sh26.92 USD
Cash/Share26.78 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.8 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)284.96 USD
Upside (mean)+92.8%
Target Range180.00 USD – 410.00 USD
180.00+92.8% to mean410.00
# Analysts27
Ownership
Shares Out.133.94M
Float133.62M
Insiders0.20%
Institutions105.59%
Short Interest
Short Ratio2.6d
Short % Float5.44%
Short % Out.4.08%
Shares Short5.47M
Short (prev mo.)7.71M
Technical
SMA 50217.12 (-31.9%)
SMA 200274.59 (-46.2%)
Beta0.44
S&P 52W Chg12.08%
Avg Vol (30d)2.69M
Avg Vol (10d)3.20M
Technical Indicators
RSI (14)28.0
MACD-18.2993
MACD Signal-18.7181
MACD Hist.+0.4188
BB Upper230.33 USD
BB Middle172.23 USD
BB Lower114.14 USD
BB Width67.46%
ATR (14)9.727 USD
Vol Ratio (20d)0.63x

About Alnylam Pharmaceuticals (NASDAQ: ALNY)

›

Alnylam Pharmaceuticals (NASDAQ: ALNY) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 2,500 employees.

The shares were at 147.82 USD on 19 November 2026, down 66.0% over 52 weeks. Its 52-week range is 146.51 USD to 479.79 USD, and it trades at the bottom of that range.

At a market capitalisation of 19.80B USD, it trades at 7.5 times trailing earnings and 14.9 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 34.5, a discount of 78% for ALNY.

Alnylam Pharmaceuticals reports return on equity of 39.8%, an operating margin of 19.5% and revenue up 16.7% year over year.

It holds more cash than debt, a net cash position of 590.40M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 27 analysts cover the stock, with an average rating of Buy; their mean price target of 284.96 USD is 92.8% above the current price. The next earnings report is expected on 11 February 2027.